Announcements Trials
Browse Landscape

Phase

Phase 3 15Phase 2 13Phase 1/2 6Phase 1 4Phase 4 2

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 2NIH 1NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3Plasma cell 1Other hematologic neoplasm 1

Conditions

Lymphoma, Follicular 2Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Leukemia, T-Cell 1Leukemia, Lymphoid 1

Interventions

pembrolizumab 109Paclitaxel 65Cyclophosphamide 65Cisplatin 60Carboplatin 56Gemcitabine 48Radiotherapy 45Nivolumab 44fludarabine 38Docetaxel 38Pemetrexed 33Dexamethasone 32Capecitabine 32Lenalidomide 26fludarabine phosphate 25Rituximab 25Radiation 25Ipilimumab 25Doxorubicin 25Irinotecan 24Bevacizumab 24Azacitidine 24Vorinostat 23Vincristine 22Cytarabine 22Temozolomide 20Etoposide 20Oxaliplatin 19Fluorouracil 19atezolizumab 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Has results × Prednisolone × Clear all
NCT03792256 2025-03-21

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Children's Oncology Group

Phase 1 Completed
12 enrolled 24 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphoid, Recurrence, Leukemia, T-Cell, Lymphoma, T-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04599634 2025-02-04

Venetoclax With Obinutuzumab and Magrolimab (VENOM) in Relapsed and Refractory Indolent B-cell Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
11 enrolled 16 charts
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT01370694 2019-03-15

Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001)

Merck Sharp & Dohme LLC

Phase 1 Terminated
7 enrolled 7 charts
Lymphoid

Lymphoma, Follicular

NCT00985959 2013-12-02

A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

Janssen Pharmaceutical K.K.

Phase 1 Completed
101 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡